证券代码：603087 证券简称：甘李药业 公告编号：2025-065 甘李药业股份有限公司 关于注销回购股份并减少注册资本暨通知债权人的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、本次回购股份注销并减少注册资本的情况暨通知债权人的原因 于调整回购股份用途的议案》。对回购股份用途进行调整，由"用于实施员工持 股计划或者股权激励"调整为"用于注销减少公司注册资本"。除上述回购股份 的用途存在调整外，回购股份方案的其他内容未发生实质变化。以上议案已由 内容详见公司于 2024 年 10 月 23 日在上海证券交易所披露的《关于调整回购股 份用途的公告》（公告编号：2024-081）；2024 年 11 月 9 日在上海证券交易所披 露的《2024 年第二次临时股东大会决议公告》（公告编号：2024-091）。 自 2024 年 9 月 5 日至 2025 年 9 月 4 日公司累计通过回购专用证券账户以集 中竞价交易方式实施回购股份 3,540,021 股，占公司总股本的比例为 0.5890%， 成交最高价为 45 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 回购方案首次披露日 2024/9/6 回购方案实施期限 2024 年 9 月 5 日~2025 年 9 月 4 日 预计回购金额 15,000万元~30,000万元 回购价格上限 62.76元/股 √减少注册资本 回购用途 □用于员工持股计划或股权激励 □为维护公司价值及股东权益 实际回购股数 354.0021万股 实际回购股数占总股本比例 0.5890% 实际回购金额 15,006.9654万元 实际回购价格区间 37.65元/股~45.14元/股 一、 回购审批情况和回购方案内容 证券代码：603087 证券简称：甘李药业 公告编号：2025-064 甘李药业股份有限公司 甘李药业股份有限公司（以下简称"公司"）于 2024 年 9 月 5 日召开第四届 董事会第二十三次会议审议通过了《关于以集中竞价交易方式回购公司股份方案 的议案》 ，同意公司以自有资金通过集中竞价交易方式回购公司已发行的部分人民 币普通股（A 股）股票。回购的股份拟用于员工持股计划或股权激 ...

Group 1 - Gannee Pharmaceutical has completed a share buyback, acquiring a total of 3.540021 million shares, which represents 0.589% of the company's total share capital [1] - The highest transaction price during the buyback was 45.14 CNY per share, while the lowest was 37.65 CNY per share, with an average buyback price of 42.39 CNY per share [1] - The total amount spent on the buyback was approximately 150 million CNY [1] Group 2 - For the year 2024, Gannee Pharmaceutical's revenue composition is entirely from the pharmaceutical manufacturing industry, accounting for 100.0% [1] - The current market capitalization of Gannee Pharmaceutical is 45 billion CNY [2]

证券代码：603087 证券简称：甘李药业 公告编号：2025-064 甘李药业股份有限公司 关于股份回购实施结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/9/6 | | | | | | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 月 2024 9 9 4 | 5 | 日~2025 | 年 | 日 | | 预计回购金额 | 15,000万元~30,000万元 | | | | | | 回购价格上限 | 62.76元/股 | | | | | | 回购用途 | √减少注册资本 □用于员工持股计划或股权激励 | | | | | | | □为维护公司价值及股东权益 | | | | | | 实际回购股数 | 354.0021万股 | | | | | | 实际回购股数占总股本比例 | 0.5890% | | | | | | 实际回购金额 | 15,006.9654万元 | | | | | | 实际回购价 ...

证券代码：603087 证券简称：甘李药业 公告编号：2025-065 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、本次回购股份注销并减少注册资本的情况暨通知债权人的原因 中竞价交易方式实施回购股份 3,540,021 股，占公司总股本的比例为 0.5890%， 成交最高价为 45.14 元/股，成交最低价为 37.65 元/股，已支付的资金总额约为人 民币 15,006.9654 万元（不含交易费用），公司本次回购方案已实施完毕。具体内 容详见公司于 2025 年 9 月 8 日在上海证券交易所披露的《关于股份回购实施结 果暨股份变动的公告》（公告编号：2025-064）。 二、需债权人知晓的相关信息 上述回购股份 3,540,021 股注销完成后，公司总股本将由 601,065,290 股减少 至 597,525,269 股，注册资本将由 601,065,290 元减少至 597,525,269 元（鉴于公 司前次回购注销部分限制性股票并减少注册资本尚未完成，公司总股本暂按 601,065,290 股计算，最终 ...

Core Viewpoint - 甘李药业 has shown significant growth in stock price and financial performance, indicating strong market interest and operational success [1][2]. Financial Performance - As of June 30, 甘李药业 reported a revenue of 2.067 billion yuan, representing a year-on-year increase of 57.18% [2]. - The net profit attributable to shareholders reached 604 million yuan, marking a substantial growth of 101.96% compared to the previous year [2]. - Cumulatively, the company has distributed 1.612 billion yuan in dividends since its A-share listing, with 1.018 billion yuan distributed over the last three years [3]. Stock Performance - The stock price of 甘李药业 increased by 69.72% year-to-date, with a recent 5-day increase of 0.32%, a 20-day increase of 19.00%, and a 60-day increase of 31.04% [1]. - The stock was trading at 73.16 yuan per share, with a market capitalization of 43.974 billion yuan as of September 5 [1]. Shareholder Structure - As of June 30, the number of shareholders increased to 77,300, up by 3.08% from the previous period [2]. - The average number of circulating shares per shareholder decreased by 2.99% to 7,165 shares [2]. - Major shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 174,800 shares, and new entrants like Innovation Drug and Southern Alpha Mixed A [3].

8月29日，生物医药ETF（159859）盘中走强，截至发稿涨1.16%，成交额超9400万元，居同标的第 一。成分股中，荣昌生物涨超4%，爱美客、甘李药业、药明康德等跟涨。 华源证券认为，2025年，医药行业已具备多重积极发展因素，基本完成了新旧增长动能转换（创新替代 仿制，出海能力提升），创新药打开中国医药企业增长新曲线。 Wind金融终端数据显示，生物医药ETF（159859）连续三个交易日获资金净流入，累计"吸金"超6100 万元。 万和证券表示，整体来看，指数短线或将面临震荡，但板块轮动表现，不少低位滞涨的品种开启补涨走 势说明资金高低切换迹象逐步加强，市场延续结构性行情，未来降息叠加经济复苏预期，顺周期等方向 仍可重点关注。 生物医药ETF（159859）紧密跟踪国证生物医药指数（399441.SZ），该指数布局均衡，覆盖A股创新 药，CXO，疫苗，血制品多个方向。生物医药ETF（159859）为同标的规模最大、流动性最好的产品。 该ETF还配备了联接基金（A：011040，C：011041）。 （本文机构观点来自持牌证券机构，不构成任何投资建议，亦不代表平台观点，请投资人独立判断和决 策。） 此 ...

Market Overview - The biopharmaceutical sector experienced a slight decline of 0.14% on August 28, with Kanghong Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3843.6, up 1.14%, while the Shenzhen Component Index closed at 12571.37, up 2.25% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Xizang Pharmaceutical (600211) with a closing price of 48.83, up 9.00% and a trading volume of 375,100 shares, totaling 1.83 billion yuan [1] - Wendi Pharmaceutical (688488) closed at 17.78, up 5.39% with a trading volume of 137,700 shares, totaling 235 million yuan [1] - Rili Pharmaceutical (603087) closed at 71.48, up 4.40% with a trading volume of 221,400 shares, totaling 1.54 billion yuan [1] - Conversely, Kanghong Pharmaceutical (002773) saw a decline of 3.36%, closing at 39.36 with a trading volume of 173,800 shares, totaling 676 million yuan [2] - Other notable decliners included: - Bohui Innovation (300318) down 3.23% to 5.99 [2] - Jinzhenke (688670) down 3.14% to 15.40 [2] Capital Flow - The biopharmaceutical sector experienced a net outflow of 888 million yuan from institutional investors, while retail investors saw a net inflow of 941 million yuan [2] - The capital flow for specific stocks showed: - Xizang Pharmaceutical had a net inflow of 2.26 billion yuan from institutional investors, while retail investors had a net outflow of 547.24 million yuan [3] - Ganli Pharmaceutical saw a net inflow of 79.74 million yuan from institutional investors, with retail investors experiencing a net outflow of 21.51 million yuan [3]

Core Insights - The Chinese biopharmaceutical industry is experiencing a surge in performance, with 69.23% of 39 innovative drug companies reporting positive net profit growth in their semi-annual reports [1] - Six companies reported over 100% year-on-year growth in net profit, indicating strong development momentum in the sector [1] Company Performance - **Kexing Pharmaceutical** achieved the highest net profit growth at 576.45%, totaling 0.80 billion yuan, focusing on antiviral, oncology, and immunology treatments [1] - **Sanno Bio** reported a 308.29% increase in net profit, reaching 0.89 billion yuan, driven by significant growth in raw material drug sales [2][3] - **Jinkai Biotechnology** saw a 123.61% increase in net profit, providing custom development services for small molecule drugs [3] - **Wuxi AppTec** and **Hengrui Medicine** also ranked among the top three companies by revenue, with 207.99 billion yuan and 157.61 billion yuan respectively [4] Industry Trends - The industry is transitioning from an "investment phase" to a "harvest phase," indicating a recovery in profitability and a moderate expansion stage [4] - Recent policy measures from the National Healthcare Security Administration aim to support high-quality development in innovative drug research and market application [4] - Analysts predict that the innovative drug sector will continue to thrive, driven by efficiency and cost advantages in drug development [5]

Summary of Key Points Core Viewpoint - The announcement details the completion of a share reduction plan by a senior executive of Ganli Pharmaceutical, confirming that the reduction was executed as planned without any discrepancies. Group 1: Executive Shareholding and Reduction Plan - Prior to the reduction, the senior executive, Sun Cheng, held 530,200 shares, representing 0.088% of the company's total share capital [1] - The reduction plan disclosed on July 5, 2025, indicated that Sun Cheng intended to reduce his holdings by up to 20,000 shares, which is 3.77% of his total shares and 0.0033% of the company's total share capital [1] - On August 19, 2025, Sun Cheng successfully reduced his holdings by 20,000 shares, equating to 0.0033% of the company's total share capital, thus completing the reduction plan [1] Group 2: Implementation Results - The reduction plan was fully implemented as per the disclosed schedule [1] - The actual reduction matched the previously disclosed plan, confirming that the minimum reduction quantity was achieved [1] - There was no early termination of the reduction plan, indicating adherence to the original timeline [1]